Daiichi Sankyo Company Limited has announced that on Friday, June 19, its generics subsidiary, Daiichi Sankyo Espha, will launch seven new generic drugs with four new active ingredients.
The generic drugs to be launched are:
1. Naftopidil OD Tablets 25mg/50mg/75mg DSEP: indicated for the treatment of urination disorder due to enlargement of prostate (Brand: Flivas OD Tablets 25mg, 50mg, 75mg)
2. Metformin Hydrochloride Tablets 250mg/500mg MT: a Biguanide-type oral hypoglycemic agent (Brand: Metgluco Tablets 250mg, 500mg)
3. Letrozole Tablets 2.5mg DSEP: an aromatase inhibitor/postmenopausal breast cancer treatment (Brand: Femara Tablets 2.5mg)
4. Oxaliplatin I.V. Infusion Solution 200mg DSEP; additional strength of formula released in 50mg, 100mg in Dec. 2014: an anti-malignant tumor agent (Brand: Elplat I.V. Infusion Solution 200mg)